Retrovirology



Poster presentation

Open Access

Clinical management of children diagnosed with HIV and hepatitis C virus infection

Kirsty England*1, Claire Thorne1, Lucy Pembrey1 and Marie-Louise Newell1,2

Address: ¹MRC Centre of Epidemiology for Child Health, Institute of Child Health, University College London, London, WC1N 1EH, UK and ²Africa Centre for Health and Population Studies, University of KwaZulu Natal, Mtubatuba 3935, South Africa

from Fourth Dominique Dormont International Conference. Host-Pathogen Interactions in Chronic Infections Paris. France. 13-15 December 2007

Published: 9 April 2008

Retrovirology 2008, 5(Suppl 1):P25 doi:10.1186/1742-4690-5-S1-P25

This abstract is available from: http://www.retrovirology.com/content/5/S1/P25

© 2008 England et al.; licensee BioMed Central Ltd.

Background

In the absence of evidence-based guidelines, we investigate current European practices for the clinical management and treatment of children coinfected with HIV and Hepatitis C virus (HCV).

Material and methods

A semi-structured questionnaire survey in clinical centres from 7 European countries who were either enrolling in the European Collaborative Study of HIV-infected pregnant women and their children or the European Paediatric HCV Network of children born to HCV-infected mothers.

Results

To date we have received responses from clinicians from 16 centres, caring for a total of 35 HIV/HCV coinfected children. Four centres were not currently following any coinfected children. Only one centre had a written policy for the management and treatment of HIV/HCV coinfected children and in most other centres (8/11, 72%) decisions regarding the care of coinfected children were taken at the hospital or departmental level with only 3 out of 11 centres relying on regional or national decisionmaking. In addition to standard laboratory tests for monitoring HIV disease (HIV RNA quantification, CD4 counts etc), 6/12 centres also performed HCV RNA PCR tests at least annually and 6/12 centres carried out ALT and AST tests at least every 6 months in coinfected children. Liver biopsy was rarely performed but liver ultrasound was performed in 5 out of 12 centres at least annually. 91% of 11

centres performed HCV genotyping on all HIV/HCV coinfected children and 88% of 8 centres monitored for evidence of hepatotoxicity in coinfected children receiving antiretroviral treatment for HIV disease. Only one centre had ever treated coinfected children for HIV and HCV infections concurrently but 4/7 other centres stated they would consider treatment at the same time if necessary. In the situation of an HIV/HCV coinfection diagnosis later in childhood, 3/7 respondents stated that they would treat HCV infection before starting HIV therapy.

Conclusions

In the absence of guidelines for the clinical management of children coinfected with HIV and HCV, practices throughout Europe vary widely. Individual centres see relatively few coinfected children and therefore a lack of experience in the management of this group and the lack of evidence-based policy may be a barrier to achieving optimal care and treatment. This survey highlights the importance of research focused on this group of children to inform guidelines for their best possible care.

Acknowledgements

We thank all the clinicians who participated in this survey.

^{*} Corresponding author